drugset / Trial / NCT01660360
Phase I Trial of Tanibirumab in Advanced or Metastatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to assess the safety, tolerability, and maximum tolerated dose (MTD) of Tanibirumab in patients with advanced or metastatic cancer who are refractory or for whom there are no standard therapeutic option. * To evaluate the pharmacokinetics of Tanibirumab in such patients * To determine a recommended phase II dose (RP2D) of Tanibirumab based on above assessments
Timeline
- Start
- 2011-11
- Primary completion
- 2013-09
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olinvacimab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Olinvacimab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Olinvacimab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | Olinvacimab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | Olinvacimab | Monoclonal antibody | 12 mg/kg | Intravenous |
| Subject | Olinvacimab | Monoclonal antibody | 16 mg/kg | Intravenous |
| Subject | Olinvacimab | Monoclonal antibody | 20 mg/kg | Intravenous |